Update 'Hypotheses: Trial Duration/dyanimcs'

Hypotheses%3A-Trial-Duration%2Fdyanimcs.md

@@ -0,0 +1,18 @@
+following line of questioning Abrantes-Metz, Adams, & Metz 
+questions revolve around the durations of trials.
+
+
+# specific questions
+
+## Does successful completion/other dynamics depend on the market for which the drug is being tested?
+
+So, for example are trials more likely to terminate if there are a lot of other drugs on that market? Are trials more likely to last longer if it is a generic or other second to market?
+
+Those types of questions can be answered by my dataset. Basically, do dynamics shift based on market saturation? How does that change across phases?
+
+
+## quantile duration
+
+- Do trials whose trial duration was in a higher quantile remain within higher quantile for later trials? i.e. are  durations stable? 
+    - Is there a policy which shuffles durations?
+- using quantile methods might allow one to create estimates including trials that are not complete.

Hypotheses%3A-Trial-Duration.md

@@ -1,10 +0,0 @@
-following line of questioning Abrantes-Metz, Adams, & Metz 
-questions revolve around the durations of trials.
-
-
-# specific questions
-## quantile duration
-
-- Do trials whose trial duration was in a higher quantile remain within higher quantile for later trials? i.e. are  durations stable? 
-    - Is there a policy which shuffles durations?
-- using quantile methods might allow one to create estimates including trials that are not complete.